Last reviewed · How we verify
NCT04535297
Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke
trial testing exposure in Parkinson Disease in 198 participants. Completed in 30 June 2020.
30 May 2020
Quick facts
| Lead sponsor | University of Haifa |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 198 |
| Start date | 10 May 2020 |
| Primary completion | 30 May 2020 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- exposure
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Stroke — all drugs for Stroke →
Sponsor
University of Haifa
Who can join
18 and older, any sex, with Parkinson Disease or Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aimed at describing the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and test the association between the patient activation level and these effects.An anonymous survey was distributed through social media and patient associations.Community-living patients with Parkinson's disease or post-stroke were invited to answer the survey.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Parkinson's Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment.
Anghelescu A, Onose G, Popescu C, Băilă M, et al · · 2022 · cited 14× · PMID 35625737 · DOI 10.3390/biomedicines10051000
Verify or expand the search:
- PubMed search for NCT04535297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of exposure
Trials testing the same drug.
- NCT06258889 — Optimizing Exposure Therapy Via Reward-focused Interventions in Individuals With Public Speaking Anxiety · NA · completed
- NCT06442852 — Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease · recruiting
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other University of Haifa trials
Trials by the same sponsor.
- NCT07379801 — The Musculoskeletal System During Puberty in Dancers With Scoliosis, and the Effect of an Exercise Program · NA · recruiting
- NCT07325929 — Online Radical Acceptance Intervention for Social Anxiety Disorder · NA · not yet recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07367763 — The Relationship Between Self-Awareness and Risk of Falls During Walking in Adults · active not recruiting
- NCT06932679 — Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04535297 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Haifa
- Last refreshed: 1 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04535297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing